Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 4/20 | 0.69 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.58 |
| ▸ | DRD3 | P35462 | 3/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.54 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.54 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | HRH2 | P25021 | 2/20 | 0.52 |
| ▸ | HRH1 | P35367 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL301254 | 0.85 | HRH3 (0.77) | LTA4HHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL14970716 | 0.84 | HRH3 (0.80) | LTA4HHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL8410557 | 0.84 | LTA4H (0.64) | LTA4HHRH3KDM4EALDH1A1MAPT | |
| SCHEMBL8122915 | 0.84 | HRH3 (0.80) | LTA4HHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL8427936 | 0.84 | LTA4H (0.70) | LTA4HHRH3DRD3DRD2PSMB1 | |
| SCHEMBL19462908 | 0.84 | LTA4H (0.64) | LTA4HHRH3DRD3DRD2KDM4E | |
| Hydrochloric Acid SCHEMBL14966041 | 0.83 | HRH3 (0.78) | LTA4HHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL7142372 | 0.82 | LTA4H (1.00) | LTA4HHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL16795220 | 0.82 | HRH3 (0.80) | LTA4HHRH3PSMB1PSMB5PSMB2 | |
| SCHEMBL4485540 | 0.81 | LTA4H (0.69) | LTA4HHRH3KDM4EALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090054472-A1 | Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof | TEIJIN PHARMA LIMITED (JP) | 2009-02-26 | — | — | US | disclosed |
| US-7473694-B2 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED (JP) | 2009-01-06 | — | — | US | disclosed |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | TEIJIN PHARMA LIMITED | 2007-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054472-A1 | Pyrazolopyrimidine Derivatives or Pharmaceutically Acceptable Salts Thereof | MAPKAPK2, MAPKAPK5, MAPKAPK3 | LTA4H 4347/4885HRH3 2746/4885DRD3 4611/4885 |
| US-20070173519-A1 | Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof | MAPKAPK2, MAPKAPK5, MAPKAPK3 | LTA4H 4347/4885HRH3 2746/4885DRD3 4611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.